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Abstract
Bayesian Additive Regression Trees (BART) is a flexible machine learning algorithm ca-
pable of capturing nonlinearities between an outcome and covariates and interaction among
covariates. We extend BART to a semiparametric regression framework in which the con-
ditional expectation of an outcome is a function of treatment, its effect modifiers, and
confounders. The confounders, not of scientific interest, are allowed to have unspecified
functional form, while treatment and other covariates that do have scientific importance
are given the usual linear form from parametric regression. The result is a Bayesian semi-
parametric linear regression model where the posterior distribution of the parameters of the
linear part can be interpreted as in parametric Bayesian regression. This is useful in situa-
tions where a subset of the variables are of substantive interest and the others are nuisance
variables that we would like to control for. An example of this occurs in causal modeling
with the structural mean model (SMM). Under certain causal assumptions, our method can
be used as a Bayesian SMM. Our methods are demonstrated with simulation studies and an
application to dataset involving adults with HIV/Hepatitis C coinfection who newly initiate
antiretroviral therapy. The methods are available in an R package semibart.
Keywords: Bayesian Additive Regression Trees, structural mean model, antiretrovirals
1
1 Introduction
With an increased emphasis on personalized medicine [1] and dynamic treatment regimes [2],
there is need for statistical methods to evaluate potential effect modifiers. Understanding effect
modifiers for a treatment or exposure helps medical personnel, scientists, and politicians better
understand mechanisms which can lead to more effective treatment strategies or improved public
policies [3]. In this paper, we introduce a flexible methodology to provide low-dimensional
summaries of effect modification when there are a large number of confounders to be controlled
for. We implement this through a semiparametric version of Bayesian Additive Regression Trees
(BART) [4] within a generalized linear model (GLM) framework [5]. We model the confounders
(the nuisance component) using BART but allow select covariates (treatment, effect modifiers,
etc.) to have parametric form. This parametric part can include interactions and typically
represents the parameters that are of scientific interest. In practice, these parameters are often
estimated in a GLM, but our formulation permits the nuisance component to be nonparametric,
increasing efficiency when the outcome process is complex.
Summarizing effect modification can be a difficult task. An introduction to statistical meth-
ods for effect modification and interactions is found in VanderWeele [6]. In this paper, we focus
on relatively simple summaries of modifiers such as an interaction between the exposure and a
covariate. While there are situations where a one dimensional parameter will not adequately
capture a complex association, many applications assess effect modification through simple inter-
action terms [7, 8]. Our goal is simply to provide a more flexible framework in which to estimate
these parameters.
In addition, we show that under some assumptions including no unmeasured confound-
ing, our model serves as a Bayesian implementation of a structural mean model. This fits
neatly within the theory laid out in Vansteelandt and Goetghebeur [9] which details estimation
of SMMs when g-estimation is not possible, as is the case with a logit or probit link func-
tion. We provide an R package semibart to implement our method, available on GitHub
(https://www.github.com/zeldow/semibart). When there is no effect modification or the ef-
fect modification is between binary covariates, the framework developed by Hill [10] can be used.
Our model differs from Hill’s in that continuous treatments and effect modifiers are more easily
interpreted.
We demonstrate our methodology on data from a cohort of HIV/Hepatitis C co-infected
individuals who initiate antiretroviral therapy. Certain antiretrovirals are mitochondrial toxic
and known to cause liver toxicity, particularly concerning for individuals with Hepatitis C infec-
tion. In this paper, we examine two-year death rates in subjects taking antiretroviral regimens
with mitochondrial toxic drugs compared to subjects on regimens without those drugs. This
analysis is based off a previous analysis that looked at rates of liver decompensation by type of
antiretroviral regimen [11].
2
2 Background
We review some semi- and nonparametric methods for predicting an output given inputs. Let y be
an outcome and let X be predictors of y. Consider models of the form g{E(y|X)} = ω(X), where
g is a known link function and ω(x) is a function. A special case of this model is parametric linear
regression which posits that the outcome has mean ω(xi;β) =
∑p
j=1 βjxij . For the remainder
of this paper, we relax the assumption that ω(xi;β) =
∑p
j=1 βjxij , which can yield biased or
inefficient estimates if this assumption is far from the truth.
In practice, the functional form of ω(·) is unknown and so it is natural to think of it as a
random parameter. We assign a prior distribution within an appropriate function space and
estimate it with data. One such prior is the Gaussian process which induces flexibility through
its covariance function [12]. Other options for modeling ω(·) include the use of basis functions
like splines or wavelets and placing prior distributions on the coefficients [13, 14]. Splines, in
particular, have been used extensively in Bayesian nonparametric and semiparametric regression.
For example, Biller (2000) presented a semiparametric GLM where one variable is modeled using
splines and the remaining variables were part of a parametric linear model [15]. Holmes and
Mallick (2001) developed a flexible Bayesian piecewise regression using linear splines [16]. The
approach in Denison et al (1998) involved piecewise polynomials and was able to approximate
nonlinearities [17]. Biller and Fahrmeir (2001) introduced a varying-coefficient model with B-
splines with adaptive knot locations [18].
Alongside these Bayesian methods reside two of the most commonly used procedures to pre-
dict an outcome y given covariates X : generalized additive models (GAM) [19] and multivariate
adaptive regression splines (MARS) [20]. GAM allows each predictor to have its own func-
tional form using splines. However, any interactions between covariates must be specified by the
analyst, which can pose difficulties in high-dimensional problems with multi-way interactions.
Bayesian versions of GAM based on P-splines exist [21] but do not have the widespread avail-
ability in statistical software that the frequentist version does. MARS is a fully nonparametric
procedure which can automatically detect nonlinearities and interactions through basis functions
also based on splines. A Bayesian MARS algorithm has also been developed [22] but also lacks
off-the-shelf software. A third option for nonparametric estimation of Y given X is Bayesian ad-
ditive regression trees (BART), which like MARS, allows for nonlinear relationships between an
outcome and covariates and interactions between covariates, while taking a Bayesian approach
to estimation [4].
In this paper we will extend BART to a semi-parametric setting in order to meet our goal
of having a parametric form for a subset of variables of interest and a flexible model for the
nuisance variables. Before introducing our method, we provide a brief review of BART.
3
2.1 Bayesian Additive Regression Trees
Bayesian additive regression trees (BART) is an algorithm that uses sum-of-trees to predict
a binary or continuous outcome given predictors. For continuous outcomes, let Y = ω(X) + ǫ
where ǫ ∼ N(0, σ2), and ω(·) is the unknown functional relating the predictors X to the outcome
Y . For binary Y we use a probit link function so that Pr(Y = 1|X) = Φ(ω(X)), where Φ(·) is
the distribution function of a standard normal random variable. We write the BART sum-of-
trees model as ω(x) =
∑m
i=1 ωi(x;Ti,Mi), where each ωi(x) is a single tree and Ti and Mi are
the parameters that represent the tree structure and end node parameters, respectively. Each
individual tree is a sequence of binary decisions based on predictors X which yield predictions
of Y within clusters of observations with similar covariate patterns. Typically, the number of
trees m is chosen to be large and each tree is restricted to be small through regularization priors,
which restricts the influence of any single tree and allows for nonlinearities and interactions that
would be not possible with any one tree. We provide an example of a BART fit to a nonlinear
mean function y = sin(x)+ ǫ in Figure 1 over a univariate predictor space x restricted to [0, 2π],
along with comparision to the fit of a single regression tree and linear regression.
The Markov Chain Monte Carlo (MCMC) algorithm for BART incorporates Bayesian back-
fitting [23], which we summarize below. Recall that yi =
∑m
j=1 ωj(xi;Tj ,Mj) + ǫi where ǫi is
assumed zero-mean normal with unknown variance σ2. The algorithm alternates between up-
dates to the error variance σ2 and updates to the trees ωj . To update σ
2, we find the residuals
from the current fit and draw a new value for σ2. In Chipman et al. [4] and this paper, we use
a conjugate inverse χ2- distribution for the prior of σ2, so drawing a new value is also a draw
from an inverse χ2- distribution. Second, the trees ωj are updated one at a time. Starting with
ω1, we compute the residuals of the outcome by subtracting off the fit of the other m− 1 trees,
ω2, . . . , ωm. We then propose a modification for the tree ω1, which is either accepted or rejected
by a Metropolis-Hastings step. We update the trees ω2, . . . , ωm in the same fashion. More details
are available in the original BART paper [4]. In the next section, we propose a semiparametric
extension of BART, called semi-BART, where a small subset of covariates have linear functional
form and the rest are modeled with BART’s sum-of-trees.
3 Semi-BART Model
3.1 Notation
Suppose we have n independent observations. Let Y denote the outcome, which can be binary
or continuous. Let A denote treatment, which can be binary or continuous. The remaining
covariates we call X. Let L = (A,X).
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Figure 1: Illustration of a BART fit with a univariate predictor space x ∈ [0, 2π] and mean
response y = sin(x) + ǫ. The solid line is the fit using linear regression, the dashed line is the fit
of BART, and the dashed-dotted line is the fit of a single tree.
3.2 Semiparametric Generalized Linear Model
In applied research, it is common for the effects of only a few covariates to be of scientific interest,
while a larger number of covariates are needed to address confounding. Our model imposes
linearity on just this small subset of covariates, while retaining flexibility in modeling the rest
of the covariates whose exact functional form in relation to the outcome may be considered
a nuisance. We partition the predictors into two distinct subsets so that L = L1 ∪ L2 and
L1 ∩ L2 = ∅. Here, L1 represents nuisance covariates that we must control for but is not of
primary interest and L2 represents covariates that do have scientific interest, such as treatment
A and its effect modifiers. For continuous Y , we write Yi = ω(L1)+h(L2;ψ)+ ǫi, where h(·) is a
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linear function of its covariates in ψ (as in linear regression) but ω(·) is a function with unspecified
form. The errors ǫi are iid mean zero and normally distributed with unknown variance σ
2. More
generally, we write g [E(Y |L1,L2)] = ω(L1)+h(L2;ψ), for a known link function g. We call this
the semi-BART model since we estimate ω(·) using BART. Note that this implies that if L1 = L
and L2 = ∅, we have a nonparametric BART model. On the other hand if L1 = ∅ and L2 = L,
we have a fully parametric regression model. While there is no restriction on the dimensionality
of L1 and L2, we assume that that L1 is large enough such that BART is a reasonable choice of
an algorithm and that L2 contains only a few covariates that are of particular interest.
3.3 Special Case: Structural Mean Models
We now consider a special case of our semiparametric GLM from an observational study with no
unmeasured confounders, introducing additional notation specific to this section. As before, the
exposure of interest is denoted A and can be either binary or continuous. The counterfactual
Y a denotes the outcome that would have been observed under exposure A = a. For the special
case of binary A, each individual has two counterfactual outcomes – Y 1 and Y 0 – but we
observe at most one of the two, corresponding to the actual level of exposure received. That is,
Y = AY 1 + (1−A)Y 0.
Robins developed structural nested mean models to adjust for time-varying confounding
with a longitudinal exposure [24, 25]. In the case of a point treatment, structural nested mean
models are no longer nested and called structural mean models (SMMs). While time-varying
confounding with point treatments is not a concern, SMMs still parameterize a useful causal
contrast – the mean effect of treatment among the treated given the covariates [9, 26]. Write
this as:
g {E (Y a|X = x, A = a)} − g
{
E
(
Y 0|X = x, A = a
)}
= h∗(x, a;ψ∗), (1)
where g is a known link function. In this paper, we provide a Bayesian solution to (1). To do so,
we impose some restrictions on h∗(·;ψ∗), requiring that under no treatment or when there is no
treatment effect the function h∗(·;ψ∗) must equal 0. That is, h∗(x, a;ψ∗) satisfies h∗(x, 0;ψ∗) =
h∗(x, a; 0) = 0. Some examples of h∗(x, a;ψ∗) are h∗(x, a;ψ∗) = ψa or h∗(x, a;ψ∗) = (ψ1 +
ψ2x3)a, when some covariate x3 modifies to the effect of a on y.
While expression (1) cannot be evaluated directly due to the unobserved counterfactuals, two
assumptions are needed to identify it with observed data [26].
1. Consistency: If A = a, then Y a = Y ;
2. Ignorability: A ⊥ Y 0|X .
The consistency assumption asserts that we actually get to see an individual’s counterfactual
corresponding to the exposure received. Ignorability ensures the exposure A and the counter-
factual under no treatment Y 0 are independent given X . Under these two assumptions together
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with the parametric assumption of h∗(·), the contrast on the left hand side of (1) is identified,
and the SMM from (1) can be rewritten using observed variables as
g {E (Y |X,A)} = ω(L1) + h
∗(L2;ψ
∗), (2)
where ω(L1) is unspecified and h
∗(L2;ψ
∗) is a linear function of L2 [26]. Note that the left hand
side of (1) is nonparametrically identified with a third assumption, dropping the parametric
assumption of h∗(·). That is,
3. Positivity: Pr (A = a|X = x) > 0 ∀ x such that Pr(X = x) > 0.
The positivity assumption states that whenever X = x has a positive probability of occur-
ring, there is positive probability that an individual is treated. This assumption is violated in
situations where treatment is deterministic at certain levels of X = x.
Let us return briefly to our parametric choice of h∗(x, a;ψ∗), specifically let h∗(x, a;ψ∗) =
(ψ1 + ψ2x3)a. Note that the main effect of x3 is not present, guaranteeing that the restriction
h∗(x, 0;ψ∗) = h∗(x, a; 0) = 0 holds. Through this specification, the function ω(·) from equation 2
absorbs the main effect of x3 and any interactions with non-treatment covariates. Practically
speaking, we found that modeling a covariate in both h∗ and ω sometimes led to bias and
undercoverage of ψ∗ in complicated settings. Due to this, we allow the main effect of any effect
modifiers to be contained in h∗, a choice which comes with a few consequences. First, it imposes
linearity on an additional covariate. Second, the restriction h∗(x, 0;ψ∗) = h∗(x, a; 0) = 0 no
longer holds necessarily. We handle this issue by considering ω(x) and the term ψ3x3 jointly and
allowing (ψ1+ψ2x3)a to be treated separately. Third, if researchers are interested in quantifying
effect modification by x3, they might also be interested in interpreting the main effect and can
do so with semi-BART.
Hill (2012) has previously estimated causal effects on the treated using BART [10]. The
methods in that paper correspond to our setting in equation (2) where g is the identity link
function and ψ∗ is a scalar describing only an effect of treatment with no effect modification.
We extend this setup to binary outcomes, continuous-valued treatment, or where low-dimensional
summaries of effect modification are of interest, particularly with continuous effect modifiers. In
settings with continuous outcomes, binary treatment, and no effect modification (or with a binary
effect modifier), the methods presented in Hill (2012) are preferred, which we later explore in
simulations.
3.4 Computations
The algorithm for semi-BART follows the BART algorithm – briefly reviewed in Section 2.1 –
with an additional step. We solve equation (2), where ω(L1) can be written as the sum-of-trees∑m
j=1 ωj(L1;Tj,Mj). The parameter Tj contains the structure of the j
th tree; for instance,
the covariates and rules on which the tree splits. The parameters Mj contain the parameters
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governing the endnodes of the jth tree. For example, the mean of the kth endnode of the jth
tree is assumed to be normally distributed with mean µjk and variance σ
2
jk.
For continuous outcomes, we assume independent errors distributed N(0, σ2) with σ2 un-
known and proceed as follows. Initialize all values including the error variance σ2, the param-
eters ψ∗, and the tree structures Tj and Mj for j = 1, . . . ,m and iterate through the following
steps. First, update the m trees one at a time. Starting with the first tree ω1(·;T1,M1), calcu-
late the residuals by subtracting the fit of the remaining m− 1 trees at their current parameter
values as well as the fit of the linear part h∗(L2;ψ
∗). That is for the ith individual, we calculate
y∗i = yi − ω−1(L1i) − h
∗(L2i;ψ
∗), where ω−1(L1i) indicates the fit of the trees except the first
tree. As in Chipman et al. [4], a modification of the tree is now proposed. We can grow the
tree (breaking one endnode into two endnodes), prune the tree (collapse two endnodes into one),
change a splitting rule (for nonterminal nodes), or swap the rules between two nodes. We accept
or reject this modification with a Metropolis-Hastings step given the residuals y∗ = {y∗
1
, . . . , y∗n}
[27]. Once we have updated ω1(·;T1,M1), we update ω2(·;T2,M2) in the same fashion and
continue until all m trees are completed.
Next we update ψ∗, given a multivariate normal prior for ψ∗ so that p(ψ∗) ∼ MVN
(
0, σ2ψI
)
,
where I is the identity matrix of appropriate dimension and σ2ψ is large enough so that the prior
is diffuse. We calculate the residuals after subtracting off the fit of all m trees so that y∗i =
yi − ω(L1i). The posterior for ψ is multivariate normal with covariance Σψ =
[
LT
2
L2
σ2
+ I
σ2
ψ
]
−1
and mean Σψ
[
L2y
∗
σ2
+ ψ0
σ2
ψ
]
, where y∗ is the n-vector of residuals[28].
Lastly, we update the error variance σ2. We calculate the residuals given the trees ω(·)
and ψ∗ so that y∗i = yi − ω(L1i) − h(L2i;ψ
∗). With a conjugate scaled inverse χ2 distribution
for σ2 (parameters ν0 and λ0), the posterior is an updated scaled inverse χ
2 distribution with
parameters νn = ν0+n and λn = ν0λ0+ < y
∗, y∗ > where <> indicates the dot product. These
three steps are repeated until the posterior distributions are well approximated.
Our algorithm for binary outcomes with a probit link uses the underlying latent continuous
variable formulation of Albert and Chib [29], replacing the step in the algorithm that updates
the error variance σ2. Full details of the BART portion of the algorithm are available in Chipman
et al. [4], whereas our modified code for semi-BART is available at https://www.github.com/zeldow/semibart.
4 Simulation
We use simulation to compare the performance of semi-BART to competitor models when esti-
mating the regression coefficient for simulated treatment along with the coefficients for its effect
modifiers (main effects and interaction terms with treatment). Our competitors were BART
(taken from Hill [10]), GAM, and linear regression for continuous outcomes and probit regres-
sion for binary outcomes. For all simulations, we generated 500 datasets at sample sizes of
n = 500 and n = 5000, and we estimated mean bias, 95% credible/confidence interval coverage,
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and empirical standard deviation (ESD). For GAM we used the mcgv package in R along with
splines (using the s function [the function used to define smooth terms within GAM formulae]
with default settings) for continuous covariates[30]. For BART, we used the bart() function from
the BayesTree package in R with default settings[31]. The linear regression/probit regression
models were fit with the lm and glm functions in R. For semi-BART we used 10,000 MCMC
iterations including 2,500 burn-in iterations and m = 50 trees.
4.1 Scenario 1: Continuous outcome with binary treatment and no
effect modification
In the first scenario, we generated data with a continuous outcome, binary treatment, twenty
continuous covariates with a block diagonal covariance structure, and four independent binary
covariates. The data generating code is available in the appendix. The outcome was generated
as independent normal variables with variance one and mean µ(a, x) = h(a, x;ψ) + ω(x) where
h(a, x;ψ) = ψ1a and ω(x) = 1+2x1+sin(πx2x21)−2 exp(x22x24)+log | cos(
pi
2
x3)|−1.8 cos(x4)+
3x22|x2|1.5. The parameter ψ1, which encodes the treatment effect, was set to 2.
Table 1: Simulation results for scenario 1 with continuous outcome and no effect modifiers.
Method Parameter Bias Cov. ESD
n = 500
Semi-BART ψ1 -0.02 0.96 0.153
GAM ψ1 -0.02 0.94 0.371
BART ψ1 -0.02 0.94 0.153
Regression ψ1 -0.02 0.95 0.390
n = 5000
Semi-BART ψ1 0.00 0.95 0.036
GAM ψ1 0.00 0.94 0.111
BART ψ1 0.00 0.92 0.037
Regression ψ1 0.01 0.94 0.119
The results in Table 1 show that, at the smaller sample size of n = 500, all point estimates are
slightly biased in the same direction, and the 95% coverage probabilities hovered around 95%.
Notably, the ESD was over half as small for BART-based methods than for GAM or regression.
At n = 5000 the bias disappeared for all methods, and the discrepancy in ESD between the
BART-based methods and non-BART methods remained.
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4.2 Scenario 2: Continuous outcome with binary treatment and con-
tinuous effect modifier
We randomly generated 30 continuous covariates with mean zero from a multivariate normal
distribution with an autoregressive(1) covariance Σ with ρ = 0.5 with the diagonal containing
ones. That is,
Σ =


1 ρ ρ2 ρ3 · · ·
ρ 1 ρ ρ2 · · ·
ρ2 ρ 1 ρ · · ·
ρ3 ρ2 ρ 1 · · ·
...
...
...
...
. . .


.
4.2.1 Part a: simple treatment mechanism and nonlinear mean function
Given the covariates x1 − x30, the treatment was generated as a Bernoulli random variable
with probability pa = logit
−1 (0.1 + 0.2x1 − sin(x3)/3− 0.1x22). The outcome was generated as
independent random normal variables with variance one and mean µ(a, x) = h(a, x;ψ) + ω(x)
where h(a, x) = ψ1a+ψ2a∗x1+ψ3x1 and ω(x) = 1+sin(πx6x21)−exp(x4x5/5)+log | cos(
pi
2
x7)|−
1.8 cos(x8)+ 0.2x10|x6|1.5. The true values for the parameters are ψ1 = 2, ψ2 = −1, and ψ3 = 2.
Results for these simulations are shown in Table 2. The estimated parameters are unbiased
and have coverage near 95% for both sample sizes and all estimators. The ESD for all parameters
is smaller with semi-BART than it is with GAM or linear regression. This improvement of semi-
BART over GAM comes from the fact that covariate interactions are detected in the semi-BART
procedure, whereas they must be pre-specified in this implementation of GAM.
4.2.2 Part b: complex treatment mechanism and complex mean function
We also performed these simulations with different treatment and outcome data generating
functions. Here, given the covariates x1−x30, the treatment was generated as a Bernoulli random
variable with probability pa = logit
−1(0.1+ 0.2x1− 0.5x2− 0.1x1x2 +0.3x4 +0.1x5 +0.7x4x5−
0.4x11x22 − 0.4x210x15). The outcome was generated as independent random normal variables
with variance one and mean µ(a, x) = h(a, x;ψ)+ω(x) where h(a, x) = ψ1a+ψ2a∗x1+ψ3x1 and
ω(x) = 1−x2+2x3−1.5x4−0.5x5−2x6+x23−x
2
6
+2x3x4−x2x6+0.5x5x6−0.2x2x3x4+x6x8x9−
x7x21x24x25+x10x13x14x26−x24x225x10+3x3x
2
16−3x4x
2
17+x3x4x9x14−x3x4x9x
2
14+1.5x10x21.
The true values for the parameters are ψ1 = 2, ψ2 = −1, and ψ3 = 2.
Results for these simulations are shown in Table 3. At n = 500, semi-BART yielded biased
estimates (average of −0.07) for ψ3, the main effect of the effect modifier. On the other hand,
GAM and linear regression were unbiased for ψ3 but had varying degrees of bias for the treatment
effect ψ1 of −0.05 and 0.36, respectively. Semi-BART had slight undercoverage for all parameters
– 90% to 92%. At n = 5000, semi-BART was unbiased for ψ1 and ψ2, and the bias of ψ3
attenuated (−0.12 down to −0.03). For GAM and linear regression, the bias of ψ1 persisted.
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Table 2: Simulation results for scenario 2a: continuous outcome with simple treatment mecha-
nism and nonlinear outcome. The true parameters are ψ1 = 2, ψ2 = −1, and ψ3 = 2.
Method Parameter Bias Cov. ESD
n = 500
Semi-BART
ψ1 -0.01 0.94 0.123
ψ2 0.01 0.94 0.121
ψ3 0.00 0.96 0.095
GAM
ψ1 -0.01 0.93 0.135
ψ2 0.01 0.94 0.127
ψ3 0.00 0.93 0.102
Regression
ψ1 -0.01 0.94 0.166
ψ2 0.01 0.94 0.167
ψ3 0.00 0.94 0.127
n = 5000
Semi-BART
ψ1 0.00 0.95 0.034
ψ2 0.00 0.94 0.033
ψ3 0.00 0.96 0.023
GAM
ψ1 0.00 0.94 0.038
ψ2 0.00 0.94 0.039
ψ3 0.00 0.96 0.031
Regression
ψ1 0.00 0.95 0.049
ψ2 0.00 0.95 0.049
ψ3 0.00 0.95 0.038
Coverage rates were all around 95% save for ψ3 using semi-BART, which was at 89%. The ESD
was notably smaller for semi-BART than the competitors.
4.3 Scenario 3: Binary outcome with binary treatment and continuous
effect modifier
As in scenario 2, we randomly generated 30 continuous covariates with mean zero from a mul-
tivariate normal distribution with an autoregressive(1) covariance structure with ρ = 0.5 with
the diagonal containing ones. The treatment was generated as a Bernoulli random variable
with probability pa = logit
−1(0.1 + 0.2x1 − sin(x3)/3 − 0.1x22). The outcome was generated
as random Bernoulli variable with probability py(a, x) = φ [h(a, x;ψ) + ω(x)] with h(a, x;ψ) =
ψ1a+ψ2ax1+ψ3x1 and ω(x) = 0.1−sin(πx6x21/4)+exp(x6/5)x11/4−0.12x8x9x21+0.05x7x9x
2
10.
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Table 3: Simulation results for scenario 2b: continuous outcome with complex treatment and
outcome functions. The true parameters are ψ1 = 2, ψ2 = −1, and ψ3 = 2.
Method Parameter Bias Cov. ESD
n = 500
Semi-BART
ψ1 0.00 0.92 0.460
ψ2 -0.01 0.92 0.459
ψ3 -0.12 0.90 0.361
GAM
ψ1 -0.05 0.95 0.654
ψ2 -0.02 0.92 0.672
ψ3 0.00 0.93 0.520
Regression
ψ1 0.36 0.92 0.731
ψ2 -0.03 0.95 0.741
ψ3 -0.01 0.95 0.582
n = 5000
Semi-BART
ψ1 0.00 0.96 0.081
ψ2 0.00 0.93 0.090
ψ3 -0.03 0.89 0.071
GAM
ψ1 -0.07 0.94 0.213
ψ2 0.00 0.95 0.200
ψ3 0.00 0.97 0.151
Regression
ψ1 0.39 0.60 0.230
ψ2 -0.01 0.95 0.220
ψ3 -0.01 0.96 0.166
The true values for the parameters of interest are ψ1 = 0.3, ψ2 = −0.1, and ψ3 = 0.1.
The results for these simulations are shown in Table 4. For semi-BART, there is some bias
on ψ1 at n = 500, but this vanishes at n = 5000. Overall, bias is small and coverage good for
both probit regression and semi-BART. Using probit regression is slightly more efficient than
semi-BART at n = 500 (based on ESD) but these differences mostly disappear at n = 5000.
4.4 Scenario 4: Continuous outcome with misspecified mean function
As before, we randomly generated 30 continuous covariates with mean zero from a multivariate
normal distribution with an autoregressive(1) covariance structure. The treatment was generated
as a Bernoulli random variable with probability pa = logit
−1 (0.1 + 0.2x1 − sin(x3)/3− 0.1x22).
The outcome was generated as independent random normal variables with variance one and mean
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Table 4: Simulation results for Scenario 3: Binary outcome with binary treatment and continuous
effect modifier. The true parameter values are ψ1 = 0.3, ψ2 = −0.1, and ψ3 = 0.1
Method Parameter Bias Cov. ESD
n = 500
Semi-BART
ψ1 0.03 0.92 0.144
ψ2 0.00 0.94 0.140
ψ3 0.00 0.93 0.106
Regression
ψ1 -0.01 0.93 0.131
ψ2 0.01 0.94 0.127
ψ3 -0.01 0.94 0.101
n = 5000
Semi-BART
ψ1 0.00 0.94 0.039
ψ2 0.00 0.95 0.039
ψ3 0.00 0.94 0.029
Regression
ψ1 -0.03 0.84 0.038
ψ2 0.01 0.93 0.036
ψ3 -0.01 0.93 0.029
µ(a, x) = h(a, x;ψ) + ω(x) with h(a, x;ψ) = ψ1a and ω(x) = 1 + sin(πx6x21) − exp(x4x5/5) +
log | cos(πx7/2)| − 1.8 cos(x8) + 0.2x10|x6|1.5 + x1x2 − 0.5x21 − cos(x1). However, we posited the
relationship h(a, x;ψ) = ψ1a+ψ2ax1+ψ3x1. Since the effect of x1 is actually contained in ω(x),
this is a misspecified model. The true value of ψ1 was 2.
The results for these simulations are shown in Table 5. All methods have no bias and good
coverage for ψ1. There is a slight improvement in terms of ESD for semi-BART compared to its
competitors.
5 Data Application
To illustrate our method we analyzed data from the Veterans Aging Cohort Study (VACS) in
the years 2002 to 2009, which is a cohort of patients being treated at Veterans Affairs facilities
in the United States. Our study sample consisted of patients with HIV/Hepatitis C coinfection
who were newly initiating antiretrovirals (including at least one nucleoside reverse transcriptase
inhibitor [NRTI]) and had at least six months of observations recorded in VACS prior to initiation.
Certain NRTIs are known to cause mitochrondial toxicity. These mitochrondial toxic NRTIs
(mtNRTIs) include didanosine, stavudine, zidovudine, and zalcitabine [32]. While these drugs
are no longer part of first line HIV treatment regimens, they are still used in resource-limited
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Table 5: Simulation results for scenario 4: continuous outcome and misspecified mean function.
The true value of ψ1 is 2.
Method Parameter Bias Cov. ESD
n = 500
Semi-BART ψ1 0.01 0.95 0.143
GAM ψ1 0.00 0.92 0.153
Regression ψ1 0.01 0.96 0.177
n = 5000
Semi-BART ψ1 0.00 0.92 0.041
GAM ψ1 0.00 0.93 0.048
Regression ψ1 0.00 0.95 0.060
settings or in salvage regimens [33].
Exposure to mtNRTIs may increase the risk of hepatic injury which in turn may increase
the risk of hepatic decompensation and death [34]. The goal of this analysis was to determine
if initiating an antiretroviral regimen containing a mtNRTI increased the risk of death versus
antiretroviral containing a NRTI that is not a mtNRTI. VACS data contains a number of variables
confounding the relationship between mtNRTI use and death including subject demographics,
year of antiretroviral initiation, HIV characteristics such as CD4 count and HIV viral load,
concomitant medications, and laboratory measures relating to liver function.
One of the covariates included in our analysis is Fibrosis-4 (FIB-4), an index that measures
hepatitic fibrosis with higher values indicating larger injury. Specifically FIB-4 > 3.25 (no units)
indicates advanced hepatic fibrosis. FIB-4 is calculated as [35]:
[age (years)×AST (U/L)] /
[
platelet count(109/L)×
√
ALT (U/L)
]
.
Here, AST stands for aspartate aminotransferase and ALT for alanine aminotransferase. There
is some concern in that mtNRTI use in subjects with high FIB-4 will result in higher risk of liver
decompensation and death than in subjects who have lower FIB-4. Thus, we consider FIB-4 as
a possible effect modifier of the effect of mtNRTIs on death.
The outcome is a binary indicator of death within a two-year period after the subject initiated
antiretroviral therapy. We considered only baseline values for this analysis. There were some
missing values among the predictors that were handled through a single imputation. A previous
analysis of this data used multiple imputation to handle missing covariates but found that results
were very similar across imputations[11]. All continuous covariates were centered at interpretable
values. For example, age was centered around 50 years and year of study entry was centered at
2005.
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In the first analysis we sought to determine the effect of mtNRTI use on death without
considering effect modification, and to this extent we fit a Bayesian SMM with a probit link.
The estimand can be written as
Φ−1 {E (Y a|X = x, A = a)} − Φ−1
{
E
(
Y 0|X = x, A = a
)}
= ψa, (3)
where Y is the indicator of death, A represents whether mtNRTIs were part of the antiretroviral
regimen at baseline (A = 1 if mtNRTI were included in the regimen), and X all other covariates,
including FIB-4. In the second and third analysis, we considered FIB-4 to be an effect modifier,
once as a continuous covariate and once as a binary indicator which equaled 1 whenever FIB-4
> 3.25. This estimand can be written as
Φ−1 {E (Y a|X = x, A = a)} − Φ−1
{
E
(
Y 0|X = x, A = a
)}
= ψ1a+ ψ2ax1, (4)
where x1 corresponds to the appropriate FIB-4 variable.
The analysis was conducted using m = 50 trees with 20,000 total iterations (5,000 burn-in).
The prior distribution on the ψ parameters were independent Normal(0, 42). In the first analysis
the mean estimate of the posterior distribution for ψ was 0.15 (95% credible interval [CI]: -0.02,
0.33). Notably the interval includes 0, but the direction of the point estimate indicates that
subjects initiating antiretroviral therapy with an mtNRTI had greater risk of death within 2
years than subjects initiating therapy without an mtNRTI. We can interpret this coefficient in
terms of E
(
Y 0|X = x, A = a
)
and E (Y a|X = x, A = a) from equation (3). Figure 2a shows
the value of E(Y 1|X = x, A = 1) as a function of E(Y 0|X = x, A = 1) for ψ = 0.15. As
an example, suppose the unknowable quantity E(Y 0|X = x, A = 1) = 0.20. This means that
subjects treated with a mtNRTI (A = 1) with covariates X = x would have had a probability
of death of 20% within 2 years had they been untreated (A = 0). However, given ψ = 0.15 we
see that if E(Y 0|X = x, A = 1) = 0.20 then E(Y 1|X = x, A = 1) = 0.24, an increase of 4%.
One can examine the change in probability for other base probabilities E(Y 0|X = x, A = 1) by
examining the graph in Figure 2a.
We conducted a second analysis with FIB-4 as a continuous effect modifier (centered around
3.25) with the same settings as the previous one. This analysis corresponds to the contrast
from equation (4). Here, the estimate for the main effect of mtNRTI was ψ1 = 0.18 (0.00,
0.36) and the interaction between mtNRTI use and FIB-4 was ψ2 = 0.07 (0.02, 0.12). The
results can be viewed in Figure 2b. Again, for illustration, consider the special case where
E(Y 0|X = x, A = 1) = 0.20. When FIB-4 is 3.25, then E(Y 1|X = x, A = 1) = 0.25. However,
when FIB-4 is 5.25, E(Y 1|X = x, A = 1) = 0.30.
Finally we did a third analysis with FIB-4 as a binary effect modifier (> 3.25 vs. ≤ 3.25). Here
we found that ψ1 = 0.07 (-0.12, 0.26) and ψ2 = 0.38 (0.07, 0.69). These results can be viewed
in Figure 2c. Here, we see that if E(Y 0|X = x, A = 1) = 0.20, then E(Y 1|X = x, A = 1) = 0.22
for subjects with FIB-4 ≤ 3.25 and E(Y 1|X = x, A = 1) = 0.35 for subjects with FIB-4 > 3.25.
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Figure 2: Results of data application showing the effect of having an mtNRTI in an antiretroviral
regimen on two-year death. A = 1 indicates receipt of an mtNRTI and A = 0 indicates no receipt
of an mtNRTI. The x-axis represents E(Y 0|X, A = 1) which is the mean probability of death if
the treated A = 1 had in fact been untreated A = 0 given X. This quantity is unknown so we
consider a spectrum of reasonable values. The y-axis represents E(Y 1|X, A = 1) and gives the
effect of treatment A on death relative to the x-axis. (a) We show effect of mtNRTI on death
with no effect modifiers. If E(Y 0|X, A = 1) = 0.20 then E(Y 1|X, A = 1) = 0.24. For other
values of E(Y 0|X, A = 1), identify the value on the x-axis, draw a vertical line until it hits the
causal curve, then draw a horizontal line from that point to the y-axis. (b) We consider the effect
modification of mtNRTI on death by continuous FIB-4. Assuming E(Y 0|X = x, A = 1) = 0.20,
treatment increases the causal risk of death to 25% for subjects with FIB-4 = 3.25 (solid line).
For subjects with FIB-4 = 4.25 (dotted-dashed line), the causal risk of death increases to 27%.
The causal risk of death for individuals with FIB-4 = 5.25 (dashed line) is 30%. (c) We consider
the effect modification of mtNRTI on death by a dichotomized FIB-4. The solid line indicates
the causal effect curve when FIB-4 ≤ 3.25. Assuming E(Y 0|X = x, A = 1) = 0.20, we find that
treatment increases the mean risk to 22%. The mean risk of death for individuals with high
FIB-4 > 3.25 (dashed line) is even higher at 35%.
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6 Discussion
We presented a new Bayesian semiparametric model, which can be implemented with an R pack-
age semibart that is available on the author’s GitHub page (https://github.com/zeldow/semibart).
Our model allows for flexible estimation of the nuisance component while being parametric for
covariates that are of immediate scientific interest, which provides a viable and intuitive alter-
native to fully parametric regression. Under some causal assumptions, this model can as be
interpreted as a SMM, which also provides the first fully Bayesian SMM. This is particularly
useful in the case of binary outcomes where g-estimation is not possible. Vansteelandt and
Goetghebeur [9] provided approaches for estimating SMMs with binary outcomes in frequentist
settings; our method is consistent with their suggestions but incorporates the added flexibility
of BART.
The primary limitation of our method in the causal setting is that semi-BART does not
currently accommodate instrumental variables or longitudinal treatment measures, which are
frequently used components of structural nested models. In simulations with binary outcomes,
we also found little difference in our estimates using semi-BART versus probit regression. Al-
though it is reassuring that semi-BART works as well as parametric regression, we aim to better
understand the reasons why we are seeing equivalent – rather than superior – performance of
semi-BART (versus probit regression) for binary outcomes. Lastly, we aim to extend semi-BART
to handle common link functions such as logit and log.
We imagine that our work can benefit a number of different types of researchers. In par-
ticular, we hope that semi-BART can be a viable alternative to the researcher who uses linear
regression as the default statistical method in applications. Second, we also hope to convince re-
searchers who prefer flexible machine learning algorithms, such as BART, but need interpretable
coefficients such as a treatment effect and its modifiers that semi-BART is a dependable option.
Supplementary Material
A Simulation code - data generation
A.1 Scenario 1
library(mvnfast)
p1 <- 20 # no. of continuous covariates
p2 <- 5 # no. of binary
makedata <- function(nsim, n, p1, p2, sd) {
dat4 <- array(0, dim = c(nsim, n, p1 + p2 + 1) )
for (k in 1:nsim) {
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cov <- matrix(0, p1, p1)
diag(cov) <- rep(1, p1)
for(i in 1:5) {
for(j in 1:5) {
if (i != j) cov[i,j] <- cov[j, i] <- 0.20
}
}
for(i in 6:10) {
for(j in 6:10) {
if (i != j) cov[i,j] <- cov[j, i] <- 0.15
}
}
for(i in 11:15) {
for(j in 11:15) {
if (i != j) cov[i,j] <- cov[j, i] <- 0.10
}
}
for(i in 16:20) {
for(j in 16:20) {
if (i != j) cov[i,j] <- cov[j, i] <- 0.05
}
}
mu <- c(rep(2.0, 5), rep(1.5, 5), rep(1.0, 5), rep(0.0, 5))
cont.covs <- rmvn(n, mu, sigma = cov)
bin.covs <- cbind(rbinom(n, size = 1, prob = 0.25),
rbinom(n, size = 1, prob = 0.5),
rbinom(n, size = 1, prob = 0.5),
rbinom(n, size = 1, prob = 0.75),
rbinom(n, size = 1, prob = 0.75))
x <- cbind(bin.covs, cont.covs)
## nonlinear continuous single
mu4 <- 1 + 2 * x[ , 1] + 2 * x[ , 6] + sin( pi * x[ , 2] * x[ ,7] ) - 2 * exp( x[ , 3] * x[ , 5] ) +
log( abs( cos ( pi / 2 * x[ , 8] ) ) ) - 1.8 * cos( x[ , 9]) + 3 * x[ , 3] * abs(x[ ,7]) ^ 1.5
y4 <- rnorm(n, mu4 , sd = sd)
mydat4 <- cbind(x, y4)
dat4[k, , ] <- mydat4
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}return(list( dat4 = dat4) )
}
n500_sd1 <- makedata(500, 500, 20, 5, 1)
n5000_sd1 <- makedata(500, 5000, 20, 5, 1)
A.2 Scenario 2
A.2.1 Part a
library(mvnfast)
expit <- function(x) exp(x) / (1 + exp(x))
makedata <- function(nsim, n) {
dat8 <- array(0, dim = c(nsim, n, 30 + 2) )
for (k in 1:nsim) {
p <- 30
mu <- rep(0, p)
sig <- matrix(0, nrow = p, ncol = p)
diag(sig) <- 1
rho <- 0.5
for(i in 1:(p-1)) {
for(j in (i+1):p) {
kk <- j - i
sig[i, j] <- sig[j, i] <- rho^kk
}
}
x <- rmvn(n, mu, sigma = sig)
prob.a <- expit(0.1 + 0.2 * x[,1] - sin(x[,3])/3 - 0.1 * x[,22])
a <- rbinom(n, 1, prob.a)
x <- cbind(a, x)
## nonlinear continuous -multi
mu8 <- 1 + 2 * x[ , 1] - 1 * x[ , 1] * x[ , 2] + 2 * x[ , 2] + sin( pi * x[ , 22] * x[ ,7] ) - 1 * exp( x[ , 6]/5 * x[ , 5] ) +
log( abs( cos ( pi / 2 * x[ , 8] ) ) ) - 1.8 * cos( x[ , 9]) + 0.2 * x[ , 11] * abs(x[ ,7]) ^ 1.5
y8 <- rnorm(n, mu8 , sd = 1)
mydat8 <- cbind(x, y8)
dat8[k, , ] <- mydat8
}
return(list( dat8 = dat8) )
}
n500 <- makedata(500, 500)
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n5000 <- makedata(500, 5000)
A.2.2 Part b
library(mvnfast)
expit <- function(x) exp(x) / (1 + exp(x))
makedata <- function(nsim, n) {
dat8 <- array(0, dim = c(nsim, n, 30 + 2) )
for (k in 1:nsim) {
p <- 30
mu <- rep(0, p)
sig <- matrix(0, nrow = p, ncol = p)
diag(sig) <- 1
rho <- 0.5
for(i in 1:(p-1)) {
for(j in (i+1):p) {
kk <- j - i
sig[i, j] <- sig[j, i] <- rho^kk
}
}
x <- rmvn(n, mu, sigma = sig)
prob.a <- expit(0.1 + 0.2 * x[,1] - 0.5*x[,2]-0.1*x[,1]*x[,2] + 0.3 *x[,4]+0.1*x[,5]+
0.7*x[,4]*x[,5] - 0.4*x[,11]*x[,22] - + 0.4*x[,10]^2*x[,15] - 0.1 * x[,22])
a <- rbinom(n, 1, prob.a)
x <- cbind(a, x)
## nonlinear continuous -multi
mu8 <- 1 + 2 * x[ , 1] - 1 * x[ , 1] * x[ , 2] + 2 * x[ , 2] + 2 * sin( pi * x[ , 22] * x[ ,7] ) - 1 * exp( x[ , 6]/5 * x[ , 5] ) -
log( abs( cos ( pi / 2 * x[ , 8] ) ) ) - 1.8 * cos( x[ , 9]) + 1.2 * x[ , 11] * abs(x[ ,7]) ^ 1.5
mu8 <- 1 + 2 * x[ , 1] - 1 * x[ , 1] * x[ , 2] + 2 * x[ , 2] - 1 * x[ , 3] + 2 * x[ , 4] - 1.5 * x[ , 5] - 0.5 * x[ , 6] - 2*x[,7] +
x[,4]^2 - x[,7]^2 + 2*x[,4]*x[,5] - 1 *x[,3]*x[,7] + 0.5 * x[,6]*x[,7] - 0.2*x[,3]*x[,4]*x[,5] + x[,7]*x[,9]*x[,10] - x[,8]*x[,22]*x[,25]*x[,26] +
x[,11]*x[,14]*x[,15]*x[,27] - x[,25]*x[,26]^2*x[,11] + 3*x[,4]*x[,17]^2 - 3*x[,5]*x[,18]^2 + x[,4]*x[,5]*x[,10]*x[,15] -x[,4]*x[,5]*x[,10]*x[,15]^2+
1.5*x[,11]*x[,22]
y8 <- rnorm(n, mu8 , sd = 1)
mydat8 <- cbind(x, y8)
dat8[k, , ] <- mydat8
}
return(list(dat8 = dat8) )
}
n500 <- makedata(500, 500)
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n5000 <- makedata(500, 5000)
A.3 Scenario 3
library(mvnfast)
expit <- function(x) exp(x) / (1 + exp(x))
makedata <- function(nsim, n) {
dat6 <- array(0, dim = c(nsim, n, 30 + 2) )
for (k in 1:nsim) {
p <- 30
mu <- rep(0, p)
sig <- matrix(0, nrow = p, ncol = p)
diag(sig) <- 1
rho <- 0.5
for(i in 1:(p-1)) {
for(j in (i+1):p) {
kk <- j - i
sig[i, j] <- sig[j, i] <- rho^kk
}
}
x <- rmvn(n, mu, sigma = sig)
prob.a <- expit(0.1 + 0.2 * x[,1] - sin(x[,3])/3 - 0.1 * x[,22])
a <- rbinom(n, 1, prob.a)
x <- cbind(a, x)
## nonlinear binary - multi
prob.y6 <- pnorm(0.1 + 0.3 * x[ , 1] - 0.1 * x[ , 1] * x[ , 2] + 0.1 * x[ , 2] - sin( pi / 4 * x[ , 22] * x[ , 7] ) + exp(x[,7] / 5)*x[,11]/4 -
0.12 * x[, 22] * x[ , 9] * x[ ,10] + 0.05*x[,8] * x[,10]*x[,11]^2)
y6 <- rbinom(n, size = 1, prob = prob.y6)
mydat6 <- cbind(x, y6)
dat6[k, , ] <- mydat6
}
return(list( dat6 = dat6) )
}
n500 <- makedata(500, 500)
n5000 <- makedata(500, 5000)
A.4 Scenario 4
library(mvnfast)
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expit <- function(x) exp(x) / (1 + exp(x))
makedata <- function(nsim, n) {
dat8 <- array(0, dim = c(nsim, n, 30 + 2) )
for (k in 1:nsim) {
p <- 30
mu <- rep(0, p)
sig <- matrix(0, nrow = p, ncol = p)
diag(sig) <- 1
rho <- 0.5
for(i in 1:(p-1)) {
for(j in (i+1):p) {
kk <- j - i
sig[i, j] <- sig[j, i] <- rho^kk
}
}
x <- rmvn(n, mu, sigma = sig)
prob.a <- expit(0.1 + 0.2 * x[,1] - sin(x[,3])/3 - 0.1 * x[,22])
a <- rbinom(n, 1, prob.a)
x <- cbind(a, x)
## nonlinear continuous -multi
mu8 <- 1 + 2 * x[ , 1] + sin( pi * x[ , 22] * x[ ,7] ) - 1 * exp( x[ , 6]/5 * x[ , 5] ) +
log( abs( cos ( pi / 2 * x[ , 8] ) ) ) - 1.8 * cos( x[ , 9]) + 0.2 * x[ , 11] * abs(x[ ,7]) ^ 1.5 + x[,2]*x[,3] - 0.5*x[,2]^2 - cos(x[,2])
y8 <- rnorm(n, mu8 , sd = 1)
mydat8 <- cbind(x, y8)
dat8[k, , ] <- mydat8
}
return(list( dat8 = dat8) )
}
n500 <- makedata(500, 500)
n5000 <- makedata(500, 5000)
B Additional results from data analysis
Trace plots for analysis
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Figure 3: Trace plot for analysis with no effect modification.
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Figure 4: Trace plot for analysis with continuous effect modifier.
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Figure 5: Trace plot for analysis with binary effect modifier.
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